Navigation Links
Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
Date:10/1/2013

INDIANAPOLIS, Oct. 1, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that applications for the 2014-2015 school year are now available for the 16th annual Lilly Reintegration Scholarship.  Since its inception, the program has directed more than four million dollars in tuition, books and laboratory fees to hundreds of colleges, trade and vocational schools and high school equivalency programs across the United States to fund educational pursuits of students living with bipolar disorder, schizophrenia or schizo-affective disorder. This year the program expands to include the diagnosis of major depressive disorder. Further information is available at www.reintegration.com.

"Our goal when the program was established in 1997 was to demonstrate that when proper community resources are in place, individuals battling mental illness can reintegrate into society," explained Robert Baker, M.D., vice president, global medical affairs, Lilly Bio-Medicines.  "Based upon graduation rates today, it is clear that these dedicated students are achieving well beyond preliminary program goals. They are excelling in the classroom and predominantly graduating with honors.  As part of our continuing commitment to the neuroscience community, we are pleased to expand the program to include students living with major depressive disorder."

Lilly Reintegration Scholarship students have pursued their educational goals at the University of Chicago, Massachusetts Institute of Technology and Stanford University, to name a few, as well as at more than three hundred state and private universities, community colleges and trade schools. Recent areas of study include architecture, business administration, medical lab technology, animation arts and cosmetology. An independent judging panel comprised of psychiatric care professionals review applications annually and select scholarship recipients.

"We are proud to expand the program to include students living with major depressive disorder," said Ralph Aquila, M.D., executive director of the Center for Reintegration and chairman of the Lilly Reintegration Scholarship judging panel. "More than fourteen million Americans live with major depression. They often times have difficulty performing the routine activities of daily life and experience social isolation; many are even hospitalized. We hope this program will be a source of inspiration for these students as well."

Dr. Aquila explained that after reviewing the success rate of past program participants, and seeing that their graduation rate is higher than the national average – 71 percent vs. 55.5 percent[i] – it was agreed that the program should expand the range to assist more students. "This is not like most other scholarships, as we work with each student's individual needs and we advocate for them," he noted. "When you are a Lilly Reintegration Scholar, you are not alone. You have the entire judging panel's faith in your abilities."

About the Lilly Reintegration Scholarship

The goal of the Lilly Reintegration Scholarship is to help people with schizophrenia, schizo-affective disorder, bipolar disorder or major depressive disorder acquire the educational and vocational skills necessary to reintegrate into society, secure jobs and to improve  their lives. Through the program, Eli Lilly and Company furthers its ongoing commitment to providing tools that enhance the reintegration continuum, allowing people to move their lives forward and achieve their individual potential. Further information is available at www.reintegration.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Information about Lilly is available at www.lilly.com.  

CR-LLY

[i] According to the National Center for Higher Education Management Systems: 
http://www.higheredinfo.org/dbrowser/?year=2009&level=nation&mode=graph&state=0&submeasure=27  

Refer to:
Stephanie Libous (RF|Binder), +1(212) 994-7588, Stephanie.Libous@rfbinder.com 
Morry Smulevitz (Lilly), +1(317) 651-5567, smulevitzmb@lilly.com 

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
2. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
3. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
4. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
5. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
6. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
7. Dr. Marschall S. Runge Elected to Lilly Board of Directors
8. Lilly Reports Second-Quarter 2013 Results
9. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
10. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
11. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, an ... rheumatic fever, which damaged his heart. He continued enjoying ... by June 2013, Shepherd,s heart was giving out and ... On June 20, 2013, the Mesa, Arizona ... Heart (TAH-t). Like a heart transplant, the SynCardia TAH-t ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a bit of ... you may want to consider a treatment that some have called the next great ... , Microneedling, also known as skin needling, is a procedure using a device ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly ... 2014 and up 27 percent since 2012. , The results of the 2015 ASDS ... annual increase in skin cancer treatments and the growing popularity of soft-tissue fillers and ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... Behavioral Health Population Management Platform, announced today that Enlightened Solutions has joined the ... ability to optimize the care continuum for their patients being treated for substance ...
(Date:5/5/2016)... ... ... Liposuction specialist Marcia V. Byrd, MD spoke last month at the Fat ... Louis Airport Hotel. This year’s conference was titled “Living with Lipedema and Dealing with ... in treating Lipedema. Dr. Byrd is considered one of the leading physicians in the ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Nepenthe Laboratory ... Riverbend Elementary School last week to raise non-perishable food item donations for Food for ... Nose Day” hosted on NBC. , “The goal of the assembly was to create ...
Breaking Medicine News(10 mins):